Biosimilars Could Be An Unlikely Boost For Pfizer
Seeking Alpha
Pfizer: A Look At The Musculoskeletal Drugs Division
Seeking Alpha
Could Tofacitinib Save Pfizer?
Seeking Alpha
Blockbuster buzz: 15 top therapies in late-stage development
Fierce Biotech
- AbbVie
- Actelion
- Algeta
- Alpharadin
- Anacetrapib
- Bardoxolone
- Bayer
- BG-12
- Biogen Idec
- Bristol-Myers Squibb
- darapladib
- Eliquis
- gantenerumab
- Gilead
- GS-7977
- GSK
- Immunogen
- Lundbeck
- macitentan
- Merck
- MorphoSys
- Novartis
- Odanacatib
- Pfizer
- QVA149
- Reata
- Regeneron
- REGN727
- Roche
- Sanofi
- T-DM1
- Takeda
- tofacitinib
- Vectura
- vortioxetine
Pfizer study shows tofacitinib monotherapy superior to methotrexate
Yahoo/Fly on the Wall
Is Tofacitinib One Of Pfizer's New Cash Cows?
Seeking Alpha
Pfizer's Success With Its JAK Inhibitor
Seeking Alpha